Endoplasmic reticulum (ER) oxidase 1α (ERO1α) is a glycosylated flavoenzyme that is located on the luminal side of the ER membrane, which serves an important role in catalyzing the formation of protein disulfide bonds and ER redox homeostasis. However, the role of ERO1α in myocardial hypoxia/reoxygenation (H/R) injury remains largely unknown. In the present study, ERO1α expression levels in H9C2 cardiomyocytes increased following H/R, reaching their highest levels following 3 h of hypoxia and 6 h of reoxygenation. In addition, H/R induced apoptosis, and significantly increased expression levels of ER stress (ERS) markers 78 kDa glucose‑regulated protein and C/EBP homologous protein. Moreover, the genetic knockdown of ERO1α using short hairpin RNA suppressed cell apoptosis, caspase‑3 activity, expression levels of cleaved caspase‑12 and cytochrome c in the cytoplasm. Overall, this suggested that ERO1α knockdown may protect against H/R injury. The ERS activator tunicamycin (TM) was used to counteract the ERO1α‑induced reduction in ERS; however, the percentage of apoptotic cells and the level of mitochondrial damage did not change. In conclusion, the results from the present study suggested that ERO1α knockdown may protect H9C2 cardiomyocytes from H/R injury through inhibiting intracellular ROS production and increasing intracellular levels of Ca2+, suggesting that ERO1α may serve an important role in H/R.
In this study, we aimed to investigate the hepatoprotective effects of plantagoside (PLA) against D‐galactose (D‐gal)‐induced liver injury in aged mice. PLA treatment significantly alleviated the D‐gal‐induced body weight loss and the elevated liver index in mice, and effectively reduced oxidative stress, inflammatory response, and liver tissue damage in vivo. Transcriptomic analysis identified 513 differentially expressed genes (DEGs) regulated by PLA, and enrichment analysis revealed that these genes were primarily associated with the PI3K‐Akt signaling pathway and purine metabolism. Metabolomic analysis revealed that PLA regulates purine metabolism by modulating key metabolites, such as hypoxanthine and cAMP. Integrated omics analysis suggested that PLA exerts protective effects by regulating purine metabolism, thereby enhancing antioxidant capacity and suppressing inflammation. In conclusion, PLA significantly alleviated D‐gal‐induced liver injury, reduced oxidative stress, and attenuated inflammation by regulating purine metabolism, thereby demonstrating its potential as an anti‐aging and hepatoprotective drug and providing a new theoretical basis for the treatment of age‐associated liver diseases.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern that affects nearly one-quarter of the world’s population. General control non-repressed protein 5 (GCN5), a histone acetyltransferase (HAT), has been implicated in the progression of several diseases, but its role in MASLD remains unclear. Here, we provide the experimental evidence that progressive human and male murine MASLD is driven by GCN5, but not by p300/CREB binding protein associated factor (PCAF) activation. Hepatocyte-specific GCN5 overexpression accelerates MASLD progression, whereas its ablation alleviates disease severity. Moreover, pharmacological inhibition of GCN5 with CPTH2 protects against MASLD. Metabolomics and RNA-seq analyses demonstrate that GCN5 promotes de novo lipogenesis (DNL) by upregulating SREBP1c-mediated transcription of lipogenic genes. Mechanistically, GCN5 acetylates histone H3 at the SREBP1c promoter, enhancing transcription through its intrinsic acetyltransferase activity. Our findings further identify GCN5 as a key regulator of LXRα-induced SREBP1c expression, suggesting that targeting GCN5 may selectively inhibit SREBP1c-driven DNL without impairing LXRα-mediated reverse cholesterol transport (RCT). Notably, combined treatment with the Liver X Receptor (LXR) agonist T0901317 and CPTH2 synergistically reduced lipid accumulation in vitro and in vivo, highlighting a promising therapeutic strategy for MASLD.
Background: Astragaloside IV (AS-IV), a bioactive saponin from Astragalus membranaceus, shows promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD), though its mechanisms remain unclear. Purpose: This study aimed to elucidate how AS-IV alleviates hepatic steatosis, specifically investigating its epigenetic regulation of lipogenesis. Methods: Using high-fat diet-fed mice and lipids-loaded hepatocytes, we assessed AS-IV's effects through SREBP-1c overexpression, histone acetylation analysis, and GCN5 rescue experiments. Results: AS-IV significantly reduced hepatic steatosis by suppressing SREBP-1c-mediated de novo lipogenesis. Mechanistically, it inhibited histone acetyltransferase GCN5, decreasing H3K9/H3K14 acetylation at the SREBP-1c promoter and attenuating LXRα-driven transcription. GCN5 overexpression reversed AS-IV's suppression of SREBP-1c and lipid accumulation. Conclusion: AS-IV uniquely downregulates GCN5 expression at the transcriptional level, exerting epigenetic regulation to disrupts lipogenic programming, This represents a novel multi-target approach against MASLD that connects natural product pharmacology with epigenetic modulation.
Non-alcoholic fatty liver disease (NAFLD) is a prevalent health concern globally, impacting around a quarter of the world's population. General control non-repressed protein 5 (GCN5) is histone acetyltransferases (HATs) and is closely related to the progression of multiple diseases, but the role of GCN5 in NAFLD has not been reported. In this study, our data demonstrated that performed in progressive human and murine NAFLD provided the first experimental evidence for the role of GCN5, but not p300/CREB binding protein associated factor (PCAF) activation in disease acceleration. Hepatocyte-specific overexpression of GCN5 exacerbated the progression of NAFLD, while hepatic GCN5 ablation suppressed it. CPTH2, a potent GCN5 inhibitor, protects against NAFLD. Targeted lipidomics analysis identified a pivotal role of GCN5 simultaneously promoting de novo lipogenesis (DNL) by increasing SREBP1c-mediated expression of target genes. GCN5 promotes gene expression of SREBP1c by altering the acetylation state of histone 3 in the promoter region of SREBP1c through its inherent acetyltransferase activity. Our study demonstrates that GCN5 is involved in the transcriptional regulation of LXRα-stimulated SREBP1c. Modulating GCN5 could serve as a strategy to selectively inhibit SREBP1c-mediated lipid biosynthesis while maintaining LXRα-stimulated reverse cholesterol transport (RCT). Moreover, combined administration of LXR agonist T0901317 and CPTH2 may play a synergistic lipid-lowering effect in vitro and in vivo.